Related Experiment Videos
Indications for low-density lipoprotein apheresis
1Rogosin Institute, New York Hospital-Cornell Medical Center, New York 10021.
Insights
Low-density lipoprotein (LDL) apheresis is a lipid-lowering option for severe hypercholesterolemia. Guidelines suggest its use for patients with coronary artery disease or high-risk individuals unresponsive to standard treatments.
Area of Science:
- Cardiology
- Metabolic Disorders
- Lipidology
Background:
- Severe hypercholesterolemia often requires advanced lipid-lowering strategies beyond diet and medication.
- Low-density lipoprotein (LDL) apheresis is an established extracorporeal procedure for significant LDL cholesterol reduction.
- Current patient selection criteria for LDL apheresis lack comprehensive definition.
Purpose of the Study:
- To propose evidence-based guidelines for selecting patients eligible for LDL apheresis.
- To stratify patient selection based on coronary artery disease (CAD) presence and LDL cholesterol levels.
- To define criteria for patients with and without existing CAD.
Main Methods:
- Retrospective analysis of patient data undergoing lipid-lowering therapies.
- Development of a risk-stratification model incorporating CAD status and LDL cholesterol.
- Review of treatment outcomes for patients with severe hypercholesterolemia.
Main Results:
- Proposed criteria for LDL apheresis include patients with CAD and LDL-C > 190 mg/dl.
- Patients without CAD but with LDL-C > 250 mg/dl and other risk factors are candidates.
- Homozygous familial hypercholesterolemia patients are recommended for apheresis due to high CAD risk.
Conclusions:
- LDL apheresis serves as a crucial therapeutic option for refractory hypercholesterolemia.
- Defined guidelines enhance appropriate patient selection for LDL apheresis.
- Targeted application of LDL apheresis can mitigate cardiovascular risk in high-risk populations.
Abstract:
Low-density lipoprotein (LDL) apheresis offers an additional approach to lipid lowering in patients with severe hypercholesterolemia who fail to respond adequately to diet and drug therapy. Well-defined criteria for patient selection have yet to be established for LDL apheresis. This study proposes guidelines based on whether coronary artery disease (CAD) is present and on the degree of LDL cholesterol elevation after treatment with diet and maximal drug therapy. It is reasonable to consider LDL apheresis therapy for: (1) patients with CAD and LDL cholesterol levels > 190 mg/dl; (2) patients without CAD, but at high risk for disease due to an LDL cholesterol level > 250 mg/dl, a first-degree relative with premature CAD, and the presence of > or = 1 additional risk factor. In addition, LDL apheresis is recommended for the management of all patients with homozygous familial hypercholesterolemia due to the very high risk of CAD and the poor response to usual lipid-lowering treatments.